자가 줄기세포 유전자 치료 시장 보고서(2026년)

Autologous stem cell gene therapy is a medical treatment approach in which a patient's own stem cells are collected, genetically altered to repair or introduce specific genes, and then infused back into the body to treat or potentially cure diseases. It combines gene therapy techniques with regenerative medicine to restore normal cellular functions and is commonly used in the treatment of genetic disorders and certain types of cancers.

The primary therapy types of autologous stem cell gene therapy include hematopoietic stem cell gene therapy, ex vivo gene editing, lentiviral vector-based therapy, and adeno-associated virus-based autologous therapy. Hematopoietic stem cell gene therapy refers to a treatment approach that modifies a patient's own blood-forming stem cells to correct genetic defects and restore normal biological functions. These therapies are applied across disease indications such as rare blood disorders, immunodeficiency diseases, lysosomal storage disorders, muscular dystrophy, and ocular diseases. They are developed across stages including preclinical research, clinical phase I, clinical phase II, and clinical phase III and are used by end users such as specialty hospitals, academic medical centers, gene therapy clinics, and pediatric centers.

Tariffs are influencing the autologous stem cell gene therapy market by increasing the cost of imported bioprocessing equipment, viral vectors, laboratory reagents, and advanced manufacturing technologies required for cell processing and genetic modification procedures. This is slowing research activities and treatment development, particularly in regions dependent on imported biotechnology materials such as Asia-Pacific and parts of Europe. Therapy-intensive segments such as lentiviral vector-based therapy, adeno-associated virus-based autologous therapy, and ex vivo gene editing platforms are most affected due to global supply chain dependencies. However, tariffs are also encouraging local biotechnology manufacturing, regional supplier diversification, and increased investments in domestic cell and gene therapy infrastructure ecosystems, creating long-term resilience in the market.

The autologous stem cell gene therapy market research report is one of a series of new reports from The Business Research Company that provides autologous stem cell gene therapy market statistics, including autologous stem cell gene therapy industry global market size, regional shares, competitors with a autologous stem cell gene therapy market share, detailed autologous stem cell gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous stem cell gene therapy industry. This autologous stem cell gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autologous stem cell gene therapy market size has grown exponentially in recent years. It will grow from $2.82 billion in 2025 to $3.48 billion in 2026 at a compound annual growth rate (CAGR) of 23.4%. The growth in the historic period can be attributed to growing prevalence of rare genetic disorders, increasing investment in regenerative medicine research, expansion of stem cell therapy clinical studies, rising demand for targeted treatment approaches, growing support for advanced therapeutic development.

The autologous stem cell gene therapy market size is expected to see exponential growth in the next few years. It will grow to $7.97 billion in 2030 at a compound annual growth rate (CAGR) of 23.0%. The growth in the forecast period can be attributed to increasing commercialization of personalized gene therapies, rising adoption of advanced gene editing technologies, growing investments in cell and gene therapy manufacturing facilities, increasing focus on curative treatment development, expansion of clinical pipeline activities for genetic diseases. Major trends in the forecast period include increasing adoption of personalized regenerative therapies, expansion of targeted stem cell modification approaches, growing use of patient-specific treatment strategies, increasing focus on curative therapies for rare diseases, advancement in ex vivo cellular engineering techniques.

The increasing demand for personalized medicine is expected to drive the growth of the autologous stem cell gene therapy market going forward. Personalized medicine is a healthcare approach that utilizes an individual's genetic and biological information to develop more targeted and effective treatments rather than relying on conventional one-size-fits-all therapies. The adoption of personalized medicine is rising due to advancements in genomic sequencing technologies, which enable faster and more affordable analysis of individual genetic profiles, supporting accurate diagnosis and targeted treatment selection. Autologous stem cell gene therapy advances personalized medicine by utilizing a patient's own stem cells, which are genetically modified and reintroduced into the body, allowing treatments to be specifically designed for the patient's genetic condition, improving treatment compatibility, and lowering the risk of immune rejection. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared with six in 2022, including newly approved personalized therapies introduced during 2023. Therefore, the increasing demand for personalized medicine is driving the growth of the autologous stem cell gene therapy market.

Major companies operating in the autologous stem cell gene therapy market are focusing on developing advanced solutions, such as gene therapy treatments, to facilitate precise patient-specific genetic correction and tissue regeneration for enhanced therapeutic outcomes. Gene therapy is a medical treatment approach that involves modifying, replacing, or introducing genetic material into a patient's cells to prevent, treat, or potentially cure diseases. For instance, in December 2025, Fondazione Telethon ETS, an Italy-based nonprofit biomedical foundation, received approval from the Food and Drug Administration (FDA) for Waskyra (etuvetidigene autotemcel), the first gene therapy treatment for Wiskott-Aldrich syndrome (WAS), representing a significant advancement for patients without a suitable matched stem cell donor. The treatment is an ex vivo, autologous hematopoietic stem cell gene therapy that uses the patient's own CD34+ hematopoietic stem and progenitor cells, which are collected, genetically modified using a lentiviral vector containing a functional WAS gene, and subsequently reinfused into the patient.

In June 2025, Carlyle Group and SK Capital Partners, a US-based investment company, acquired Bluebird Bio Inc. for $29 billion. Through this acquisition, Carlyle Group and SK Capital seek to enhance Bluebird Bio's commercialization efforts and financial stability to accelerate the development and global commercialization of its gene therapy treatments. Bluebird Bio Inc. is a US-based biotechnology company that provides autologous stem cell gene therapy.

Major companies operating in the autologous stem cell gene therapy market report are Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Lonza Group AG, BioNTech SE, Kite Pharma Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Sangamo Therapeutics Inc., Minaris Regenerative Medicine GmbH, Editas Medicine Inc., Intellia Therapeutics Inc., Caribou Biosciences Inc., Autolus Therapeutics plc, Rocket Pharmaceuticals Inc., JW Therapeutics Co. Ltd., CARsgen Therapeutics Holdings Limited, bluebird bio Inc., Orchard Therapeutics, CSL Behring, Genethon, Mesoblast Limited

North America was the dominating region in the autologous stem cell gene therapy market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the autologous stem cell gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the autologous stem cell gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autologous stem cell gene therapy market consists of sales of betibeglogene autotemcel, atidarsagene autotemcel, and gene-modified hematopoietic stem cell therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autologous Stem Cell Gene Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses autologous stem cell gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autologous stem cell gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The autologous stem cell gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy Type: Hematopoietic Stem Cell Gene Therapy; Ex Vivo Gene Editing; Lentiviral Vector Based Therapy; Adeno Associated Virus Based Autologous Therapy
• 2) By Disease Indication: Rare Blood Disorders; Immunodeficiency Diseases; Lysosomal Storage Disorders; Muscular Dystrophy; Ocular Diseases
• 3) By Development Stage: Preclinical Research; Clinical Phase I; Clinical Phase II; Clinical Phase III
• 4) By End User: Specialty Hospitals; Academic Medical Centers; Gene Therapy Clinics; Pediatric Centers
• Subsegments:
• 1) By Hematopoietic Stem Cell Gene Therapy: Autologous Bone Marrow Derived Stem Cell Therapy; Peripheral Blood Stem Cell Therapy; Cord Blood Stem Cell Therapy; Genetically Modified Hematopoietic Stem Cell Therapy; Non Myeloablative Stem Cell Therapy
• 2) By Ex Vivo Gene Editing: Clustered Regularly Interspaced Short Palindromic Repeats Based Editing; Transcription Activator Like Effector Nucleases Based Editing; Zinc Finger Nuclease Based Editing; Base Editing Therapy; Prime Editing Therapy
• 3) By Lentiviral Vector Based Therapy: Self Inactivating Lentiviral Vector Therapy; Replication Deficient Lentiviral Therapy; Integrating Lentiviral Vector Therapy; Non Integrating Lentiviral Vector Therapy; Personalized Lentiviral Cell Therapy
• 4) By Adeno Associated Virus Based Autologous Therapy: Single Stranded Adeno Associated Virus Therapy; Self Complementary Adeno Associated Virus Therapy; Tissue Specific Adeno Associated Virus Therapy; Engineered Capsid Adeno Associated Virus Therapy; High Capacity Adeno Associated Virus Therapy
• Companies Mentioned: Johnson & Johnson; Novartis AG; Bristol Myers Squibb Company; Vertex Pharmaceuticals Incorporated; Lonza Group AG; BioNTech SE; Kite Pharma Inc.; CRISPR Therapeutics AG; Beam Therapeutics Inc.; Sangamo Therapeutics Inc.; Minaris Regenerative Medicine GmbH; Editas Medicine Inc.; Intellia Therapeutics Inc.; Caribou Biosciences Inc.; Autolus Therapeutics plc; Rocket Pharmaceuticals Inc.; JW Therapeutics Co. Ltd.; CARsgen Therapeutics Holdings Limited; bluebird bio Inc.; Orchard Therapeutics; CSL Behring; Genethon; Mesoblast Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Autologous Stem Cell Gene Therapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Autologous Stem Cell Gene Therapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Autologous Stem Cell Gene Therapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Autologous Stem Cell Gene Therapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Personalized Regenerative Therapies
  • 4.2.2 Expansion Of Targeted Stem Cell Modification Approaches
  • 4.2.3 Growing Use Of Patient-Specific Treatment Strategies
  • 4.2.4 Increasing Focus On Curative Therapies For Rare Diseases
  • 4.2.5 Advancement In Ex Vivo Cellular Engineering Techniques

5. Autologous Stem Cell Gene Therapy Market Analysis Of End Use Industries

• 5.1 Specialty Hospitals
• 5.2 Academic Medical Centers
• 5.3 Gene Therapy Clinics
• 5.4 Pediatric Centers
• 5.5 Biotechnology Research Institutes And Cell Therapy Centers

6. Autologous Stem Cell Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Autologous Stem Cell Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Autologous Stem Cell Gene Therapy PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Autologous Stem Cell Gene Therapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Autologous Stem Cell Gene Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Autologous Stem Cell Gene Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Autologous Stem Cell Gene Therapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Autologous Stem Cell Gene Therapy Market Segmentation

• 9.1. Global Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hematopoietic Stem Cell Gene Therapy, Ex Vivo Gene Editing, Lentiviral Vector Based Therapy, Adeno Associated Virus Based Autologous Therapy
• 9.2. Global Autologous Stem Cell Gene Therapy Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rare Blood Disorders, Immunodeficiency Diseases, Lysosomal Storage Disorders, Muscular Dystrophy, Ocular Diseases
• 9.3. Global Autologous Stem Cell Gene Therapy Market, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Preclinical Research, Clinical Phase I, Clinical Phase II, Clinical Phase III
• 9.4. Global Autologous Stem Cell Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Specialty Hospitals, Academic Medical Centers, Gene Therapy Clinics, Pediatric Centers
• 9.5. Global Autologous Stem Cell Gene Therapy Market, Sub-Segmentation Of Hematopoietic Stem Cell Gene Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Autologous Bone Marrow Derived Stem Cell Therapy, Peripheral Blood Stem Cell Therapy, Cord Blood Stem Cell Therapy, Genetically Modified Hematopoietic Stem Cell Therapy, Non Myeloablative Stem Cell Therapy
• 9.6. Global Autologous Stem Cell Gene Therapy Market, Sub-Segmentation Of Ex Vivo Gene Editing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Clustered Regularly Interspaced Short Palindromic Repeats Based Editing, Transcription Activator Like Effector Nucleases Based Editing, Zinc Finger Nuclease Based Editing, Base Editing Therapy, Prime Editing Therapy
• 9.7. Global Autologous Stem Cell Gene Therapy Market, Sub-Segmentation Of Lentiviral Vector Based Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Self Inactivating Lentiviral Vector Therapy, Replication Deficient Lentiviral Therapy, Integrating Lentiviral Vector Therapy, Non Integrating Lentiviral Vector Therapy, Personalized Lentiviral Cell Therapy
• 9.8. Global Autologous Stem Cell Gene Therapy Market, Sub-Segmentation Of Adeno Associated Virus Based Autologous Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single Stranded Adeno Associated Virus Therapy, Self Complementary Adeno Associated Virus Therapy, Tissue Specific Adeno Associated Virus Therapy, Engineered Capsid Adeno Associated Virus Therapy, High Capacity Adeno Associated Virus Therapy

10. Autologous Stem Cell Gene Therapy Market Regional And Country Analysis

• 10.1. Global Autologous Stem Cell Gene Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Autologous Stem Cell Gene Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Autologous Stem Cell Gene Therapy Market

• 11.1. Asia-Pacific Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Autologous Stem Cell Gene Therapy Market

• 12.1. China Autologous Stem Cell Gene Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Autologous Stem Cell Gene Therapy Market

• 13.1. India Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Autologous Stem Cell Gene Therapy Market

• 14.1. Japan Autologous Stem Cell Gene Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Autologous Stem Cell Gene Therapy Market

• 15.1. Australia Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Autologous Stem Cell Gene Therapy Market

• 16.1. Indonesia Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Autologous Stem Cell Gene Therapy Market

• 17.1. South Korea Autologous Stem Cell Gene Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Autologous Stem Cell Gene Therapy Market

• 18.1. Taiwan Autologous Stem Cell Gene Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Autologous Stem Cell Gene Therapy Market

• 19.1. South East Asia Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Autologous Stem Cell Gene Therapy Market

• 20.1. Western Europe Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Autologous Stem Cell Gene Therapy Market

• 21.1. UK Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Autologous Stem Cell Gene Therapy Market

• 22.1. Germany Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Autologous Stem Cell Gene Therapy Market

• 23.1. France Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Autologous Stem Cell Gene Therapy Market

• 24.1. Italy Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Autologous Stem Cell Gene Therapy Market

• 25.1. Spain Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Autologous Stem Cell Gene Therapy Market

• 26.1. Eastern Europe Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Autologous Stem Cell Gene Therapy Market

• 27.1. Russia Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Autologous Stem Cell Gene Therapy Market

• 28.1. North America Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Autologous Stem Cell Gene Therapy Market

• 29.1. USA Autologous Stem Cell Gene Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Autologous Stem Cell Gene Therapy Market

• 30.1. Canada Autologous Stem Cell Gene Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Autologous Stem Cell Gene Therapy Market

• 31.1. South America Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Autologous Stem Cell Gene Therapy Market

• 32.1. Brazil Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Autologous Stem Cell Gene Therapy Market

• 33.1. Middle East Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Autologous Stem Cell Gene Therapy Market

• 34.1. Africa Autologous Stem Cell Gene Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Autologous Stem Cell Gene Therapy Market, Segmentation By Therapy Type, Segmentation By Disease Indication, Segmentation By Development Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Autologous Stem Cell Gene Therapy Market Regulatory and Investment Landscape

36. Autologous Stem Cell Gene Therapy Market Competitive Landscape And Company Profiles

• 36.1. Autologous Stem Cell Gene Therapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Autologous Stem Cell Gene Therapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Autologous Stem Cell Gene Therapy Market Company Profiles
  • 36.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Vertex Pharmaceuticals Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis

37. Autologous Stem Cell Gene Therapy Market Other Major And Innovative Companies

• BioNTech SE, Kite Pharma Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Sangamo Therapeutics Inc., Minaris Regenerative Medicine GmbH, Editas Medicine Inc., Intellia Therapeutics Inc., Caribou Biosciences Inc., Autolus Therapeutics plc, Rocket Pharmaceuticals Inc., JW Therapeutics Co. Ltd., CARsgen Therapeutics Holdings Limited, bluebird bio Inc., Orchard Therapeutics

38. Global Autologous Stem Cell Gene Therapy Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Autologous Stem Cell Gene Therapy Market

41. Autologous Stem Cell Gene Therapy Market High Potential Countries, Segments and Strategies

• 41.1 Autologous Stem Cell Gene Therapy Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Autologous Stem Cell Gene Therapy Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Autologous Stem Cell Gene Therapy Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer